ArticleAsia Pacific allergy2025
Article in Asia Pacific allergy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Objectives: This study investigated the IgE reactivity of Dp and its major allergen rDer p 2 in a cohort of allergic and nonallergic Filipinos from Ilocos Norte, Philippines. Methods: Using enzyme-linked immunosorbent assay, total IgE (n = 960), Dp-specific IgE (n = 247), and rDer p 2-specific IgE (n = 90) levels were determined. The odds ratio was used to determine the association between Dp and rDer p 2 specific IgE among selected demographic variables. An inhibition enzyme-linked immunosorbent assay was used to measure the inhibition of rDer p 2 against Dp allergen extract. Results: Among 171 allergic cases, mean IgE levels were significantly higher ( Conclusion: This study has shown the importance of Dp extract and its major allergen rDer p 2 as a source of allergen that sensitizes atopic Filipino individuals. Consequently, the inclusion of Dp and rDer p 2 in the panel of reagents utilized in immunodiagnostic and immunotherapeutic strategies and interventions for the local Filipino population sensitized to house dust mites is highly recommended.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.